Treatment decisions are increasingly guided by tumor biomarkers, including HER2 (a growth-promoting protein), PD-L1 (a marker associated with response to ICIs), and MSI-H/dMMR status (indicating genetic instability and potential sensitivity to immunotherapy) (Figure 3). This evidence concerns the gene ERBB2 and neoplasm.